Pfizer : PFE

All Pfizer Articles

1491 Articles

Jon C. Ogg | Apr 24, 2019 at 7:10 AM EDT

15 Great Dividend Stocks Retirees Should Own in 2019

Here is a slate of 15 companies that most retirees likely would want to own in their portfolio now, including…

Chris Lange | Apr 10, 2019 at 9:40 AM EDT

Unbelievable Swings in Big Pharma Short Interest

The March 29 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Apr 10, 2019 at 7:30 AM EDT

The 5 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks.

Chris Lange | Apr 2, 2019 at 11:40 AM EDT

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with…

Jon C. Ogg | Mar 27, 2019 at 3:55 PM EDT

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.

Chris Lange | Mar 27, 2019 at 8:50 AM EDT

Major Pharma Sees a Few Wild Swings in Short Interest

The March 15 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Mar 27, 2019 at 7:10 AM EDT

Pfizer and Apple Remain Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Apple and Intel above all other Dow stocks. Many…

Jon C. Ogg | Mar 25, 2019 at 12:10 PM EDT

The 10 Companies Buying Back the Most Stock

Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are…

Lee Jackson | Mar 25, 2019 at 7:25 AM EDT

5 Must-Own Merrill Lynch Income Portfolio High-Dividend Stocks

These five top stocks, all rated Buy at Merrill Lynch, come with outstanding dividends and have good growth prospects.

Jon C. Ogg | Mar 20, 2019 at 4:25 PM EDT

Why Pfizer Is Getting Deeper Into Gene Therapy

Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing…

Chris Lange | Mar 20, 2019 at 11:29 AM EDT

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.

Chris Lange | Mar 12, 2019 at 8:35 AM EDT

Big Pharma Short Interest Backs Off, With One Huge Exception

The February 28 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Mar 12, 2019 at 7:00 AM EDT

The 6 Most Shorted NYSE Stocks

Judging by the most shorted stocks traded on the New York Stock Exchange between the February 15 and February 28…

Chris Lange | Feb 28, 2019 at 8:30 AM EST

Major Pharma Sees Tremendous Rise in Short Interest

The February 15 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Feb 28, 2019 at 6:35 AM EST

The 6 Most Shorted NYSE Stocks

Judging by the most shorted stocks traded on the New York Stock Exchange between the January 31 and February 15…

1 … 29 30 31 32 33 … 100

Pfizer : PFE

All Pfizer Articles

15 Great Dividend Stocks Retirees Should Own in 2019

Unbelievable Swings in Big Pharma Short Interest

The 5 Most Shorted Dow Stocks

What’s Next for Sangamo After This Hemophilia Study

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

Major Pharma Sees a Few Wild Swings in Short Interest

Pfizer and Apple Remain Most Shorted Dow Stocks

The 10 Companies Buying Back the Most Stock

5 Must-Own Merrill Lynch Income Portfolio High-Dividend Stocks

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Big Pharma Short Interest Backs Off, With One Huge Exception

The 6 Most Shorted NYSE Stocks

Major Pharma Sees Tremendous Rise in Short Interest

The 6 Most Shorted NYSE Stocks

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Pfizer : PFE

All Pfizer Articles

15 Great Dividend Stocks Retirees Should Own in 2019

Unbelievable Swings in Big Pharma Short Interest

The 5 Most Shorted Dow Stocks

What’s Next for Sangamo After This Hemophilia Study

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

Major Pharma Sees a Few Wild Swings in Short Interest

Pfizer and Apple Remain Most Shorted Dow Stocks

The 10 Companies Buying Back the Most Stock

5 Must-Own Merrill Lynch Income Portfolio High-Dividend Stocks

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Big Pharma Short Interest Backs Off, With One Huge Exception

The 6 Most Shorted NYSE Stocks

Major Pharma Sees Tremendous Rise in Short Interest

The 6 Most Shorted NYSE Stocks

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

Featured Reads

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States